PitchBook Newsletters
Our latest Barometers; Carbon & emissions tech shifts focus; VC's high valuations and low returns; AI in drug development...
November 15, 2025   |   Read online   |   Manage your subscription
PitchBook
The Research Pitch
PE, VC and M&A
Presented by Fidelity Private Shares
Barometers: The return environment across most private market strategies has improved notably since early 2025, according to our latest Barometers report, which provides nearly real-time estimates of performance. View it here.

VC's ups and downs: Valuations and dealmaking have increased, but the liquidity market faces pressure as returns lag. Our new report breaks down the implications of this contrast. Read it here.

Comp sheets: Check out our guides on public company valuations and financials for healthtech, foodtech and medtech.
 
A message from Fidelity Private Shares  
So someone told you to get a 409a...now what?
 
You probably weren’t planning to get a 409A valuation—someone likely told you to get one. Maybe it was your lawyer, investor, or founder friend. This guide breaks down what a 409A valuation is, why it matters, and how to make sure you’re not taking a risky shortcut.
  • Learn why 409A valuations matter and what happens when they go wrong
  • Understand common myths (like 409A valuation = company value)
  • Discover the difference between algorithmic speed vs. audit-ready accuracy
  • Get real insights on what questions to ask during the draft process
Download the guide
 
A market with no maestro
Any day now, the metronome of the economy will restart and the economists, surveyors and statisticians in the federal government can resume their work generating the steady beat of economic data that is the foundation of financial markets.

Without that rhythm of new information here on the Quantitative Research desk, we've been searching for a throughline amid a clattering of mixed signals. Consumer sentiment is low, but job numbers are stable—gold prices are screaming, but businesses seem to be managing tariff-era inventories with ease.

This week, we released our latest Quantitative Perspectives report, a deep dive into the state of US PE. We have over 40 pages of charts, data and analysis to tell the story of what is happening in deals, fundraising, distributions and more.

In this report, I've been focused on the divergence in reported buyout deal metrics and our deal valuation model. The model is not terribly complex, regressing a handful of macroeconomic variables against historical deal activity. Since the back half of 2023, there has been a sustained divergence in actual deals and our estimations.
 
Detrended quarterly PE buyout deal value versus macro model-implied deal value (Z-score)

For the last two years, the model has implied a level of deal activity that didn't materialize, and in the most recent quarter, the pendulum swung back hard. Intuiting a "why" from this swing pulls at a few different threads. In 2024, the model initially began to rise due to moderating inflation. Not lower inflation, per se, but smoothing the swings.

So, is the model just implying that we're seeing the long tail of a successful hiking cycle and that the recent spike in deals is just pent-up demand? Potentially. The deal environment has been strong in 2025, finally recovering from inflation-era malaise.

Moving forward, a step in the capital cycle, one would intuit that an improvement in deal and exit activity would kickstart a new cycle of fundraising. Our distribution-driven fundraising model mirrors that assumption. Given the recent level of distributions, we expect to see buyout fundraising increase over the next 12 months as that capital gets recycled.

Our models present a summary of their inputs, and many inputs are averages of something else. The layers of smoothing baked into these indicators fail to describe how institutional investors are scrambling for liquidity, that third quarter buyout numbers are heavily weighted by a handful of blockbuster deals, and that a hot public equity market is driven by fewer than a dozen names.

So as the White House is preparing investors to not expect to see a backdated JOLTS report or October CPI print, it might be best to scratch a few layers deeper than any top-line number. A good place to start is our Q4 2025 Quantitative Perspectives: Balancing Act.
 
Have a great weekend,

Taylor Criswell, CFA
Senior Quantitative Research Analyst
Carbon & emissions tech VC deal value rebounds, but deal count hits a low
After a sluggish Q2, VC investment in carbon and emissions technologies grew to $3.5 billion in Q3 2025—a 40% increase QoQ. But the rebound masks a longer-term trend in which deal count fell to just 187, the lowest since 2020, signaling a market increasingly dominated by large deals rather than broad VC investments.

Much of the quarter's $3.5 billion came from 10 deals over $100 million, including Fermi’s $350 million Series C and Divergent's $290 million Series E. Investors are concentrating capital in fewer, more mature companies, with late-stage deals now representing two in five transactions.
 
Carbon & emissions tech VC deal activity by quarter
Sectoral focus has also shifted. Built environment technologies led in deal value at $1.5 billion, while industrial decarbonization topped deal count with 59 transactions. Both segments offer cost-saving and resilience benefits in addition to decarbonization—appealing amid economic uncertainty. while the carbon tech and land use segments, on the other hand, lagged far behind.

Regionally, North America strengthened its lead, accounting for 55.9% of YTD deal value, while Asia's share halved to just 5%. Europe also gained ground, rising to 37.2% of global deal value and narrowing the gap with North America. This concentration of capital in Western markets reflects stronger policy support and investor confidence, while Asia’s sharp decline suggests structural challenges in scaling climate tech investment.

AI decarbonization is emerging as a critical theme, with investors backing technologies that either optimize energy use or reduce datacenter emissions—an urgent need as AI adoption accelerates. Fermi’s funding round exemplifies this trend, targeting low-carbon, water-efficient AI infrastructure. Other notable deals include SiPearl’s $151 million raise for energy-efficient processors and CuspAI’s $122 million Series A to develop AI-driven materials for carbon capture.

These moves highlight how climate tech and AI are converging, creating new opportunities for investors focused on efficiency and scalability. Read more in our Q3 Carbon & Emissions Tech VC Trends report.
 
Best,

John MacDonagh
Sr. Analyst, Emerging Technology
 
Thematic Research  

AI in Drug Development

While AI is reshaping nearly every industry, its influence may prove most transformative in biopharma, where new technologies promise to address the high failure rate, lengthy development timelines and escalating costs that characterize the industry.

While these goals remain lofty, significant progress has been made in recent years, with frenzied investment in AI and a massive computing build-out fueling advancements in research productivity, drug discovery, and clinical-trial efficiency.

VC funding for AI drug development totaled $2.7 billion through the first three quarters of 2025. An emerging class of AI-native drug developers has attracted the majority of this capital, and they’ve rapidly become some of the most well-funded startups in biopharma. Xaira Therapeutics, Isomorphic Labs and Generate:Biomedicines all achieved unicorn status within their first two institutional rounds.
 

Looking ahead, AI in biopharma is entering a crucial period of validation. With several AI-discovered drugs currently in clinical trials and leading startups likely to enter the clinic within the coming years, the clinical efficacy of AI-discovered assets will become clearer.

While AI tools for experimental design and clinical-trial optimization will likely continue to be integrated into drug development, the success of AI-discovered assets will be the most significant benchmark for the technology and will have the greatest impact on the biopharma business model.

Read the report
 
Webinars & Events  
Nov. 19: In our Q4 EU Leveraged Finance Analysis & Outlook webinar, PitchBook LCD journalists and researchers will talk about where the private credit markets in Europe will take us during the rest of 2025 and beyond. Register here

Dec. 9: Analysts from PitchBook and Morningstar will discuss key considerations for evergreen funds as these vehicles become part of the allocator toolkit. Register for the webinar here.
 
 
In the News  

Our insights and data featured in the press:

 • Twenty-one deals have raised more than $1 billion in US VC-led rounds this year, matching the pandemic-era peak, raising $108 billion in aggregate through Nov. 4. [